Biology and Treatment of Myeloma
作者： Annamaria Brioli , Lorenzo Melchor , Brian A. Walker , Faith E. Davies , Gareth J. Morgan
DOI: 10.1016/J.CLML.2014.06.011
关键词: Bioinformatics 、 Treatment strategy 、 Multiple myeloma 、 Immunology 、 Sequential treatment 、 Medicine
摘要: In recent years significant progress has been made in the understanding of multiple myeloma (MM) biology and its treatment. Current strategies for treatment MM involve concept sequential blocks therapy given as an induction followed by consolidation maintenance. age characterized emerging more powerful laboratory techniques, it is primary importance to understand how this can guide development new strategies. This review focuses on genetic basis myeloma, including most common abnormalities pathways affected effects that these have discussed also light theory intraclonal heterogeneity.
core.ac.uk
clinical-lymphoma-myeloma-leukemia.com
elsevier.com
sci-hub.se 参考文章(75)
Dharminder Chauhan, Teru Hideshima, Kenneth C. Anderson, Targeting Proteasomes as Therapy in Multiple Myeloma Advances in Experimental Medicine and Biology. ,vol. 615, pp. 251- 260 ,(2008) , 10.1007/978-1-4020-6554-5_12
Thierry Facon, Meletios A. Dimopoulos, Angela Dispenzieri, John V. Catalano, Andrew R Belch, Cyrille Hulin, Michele Cavo, Antonella Pinto, Katja Weisel, Heinz Ludwig, Nizar J. Bahlis, Anne Banos, Mourad Tiab, Michel Delforge, James D Cavenagh, Catarina Geraldes, Je-Jung Lee, Christine I. Chen, Albert Oriol, Javier De La Rubia, Lugui Qiu, Darrell J. White, Daniel Binder, Kenneth C. Anderson, Philippe Moreau, Michel Attal, Robert Knight, Guang Chen, Jason Van Oostendorp, Christian J. Jacques, Annette Ervin-Haynes, Lofti Benboubker, Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT) Blood. ,vol. 122, pp. 2- 2 ,(2013) , 10.1182/BLOOD.V122.21.2.2
Rafael Fonseca, Richard J. Bailey, Gregory J. Ahmann, S. Vincent Rajkumar, James D. Hoyer, John A. Lust, Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Gordon W. Dewald, Genomic abnormalities in monoclonal gammopathy of undetermined significance Blood. ,vol. 100, pp. 1417- 1424 ,(2002) , 10.1182/BLOOD.V100.4.1417.H81602001417_1417_1424
MH Bakkus, C Heirman, I Van Riet, B Van Camp, K Thielemans, Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation Blood. ,vol. 80, pp. 2326- 2335 ,(1992) , 10.1182/BLOOD.V80.9.2326.2326
Michael Hallek, P. Leif Bergsagel, Kenneth C. Anderson, Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process Blood. ,vol. 91, pp. 3- 21 ,(1998) , 10.1182/BLOOD.V91.1.3
Christina M. Annunziata, R. Eric Davis, Yulia Demchenko, William Bellamy, Ana Gabrea, Fenghuang Zhan, Georg Lenz, Ichiro Hanamura, George Wright, Wenming Xiao, Sandeep Dave, Elaine M. Hurt, Bruce Tan, Hong Zhao, Owen Stephens, Madhumita Santra, David R. Williams, Lenny Dang, Bart Barlogie, John D. Shaughnessy, W. Michael Kuehl, Louis M. Staudt, Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma Cancer Cell. ,vol. 12, pp. 115- 130 ,(2007) , 10.1016/J.CCR.2007.07.004
Carlo C Maley, Patricia C Galipeau, Jennifer C Finley, V Jon Wongsurawat, Xiaohong Li, Carissa A Sanchez, Thomas G Paulson, Patricia L Blount, Rosa-Ana Risques, Peter S Rabinovitch, Brian J Reid, Genetic clonal diversity predicts progression to esophageal adenocarcinoma Nature Genetics. ,vol. 38, pp. 468- 473 ,(2006) , 10.1038/NG1768
Gareth J. Morgan, Brian A. Walker, Faith E. Davies, The genetic architecture of multiple myeloma Nature Reviews Cancer. ,vol. 12, pp. 335- 348 ,(2012) , 10.1038/NRC3257
Annamaria Brioli, Kevin D. Boyd, Martin F. Kaiser, Charlotte Pawlyn, Ping Wu, Walter M. Gregory, Roger Owen, Fiona M. Ross, Graham H. Jackson, Michele Cavo, Faith E. Davies, Gareth J. Morgan, Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy British Journal of Haematology. ,vol. 161, pp. 291- 294 ,(2013) , 10.1111/BJH.12218
Marta Chesi, P. Leif Bergsagel, Molecular pathogenesis of multiple myeloma: basic and clinical updates International Journal of Hematology. ,vol. 97, pp. 313- 323 ,(2013) , 10.1007/S12185-013-1291-2